%0 Journal Article
%A Apostolidis, Leonidas
%A Lang, Kristin
%A Sisic, Leila
%A Busch, Elena
%A Ahadova, Aysel
%A Wullenkord, Ramona
%A Nienhüser, Henrik
%A Billeter, Adrian
%A Müller-Stich, Beat
%A Kloor, Matthias
%A Jaeger, Dirk
%A Haag, Georg Martin
%T Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment.
%J Journal of cancer research and clinical oncology
%V 149
%N 4
%@ 0171-5216
%C Berlin
%I Springer
%M DKFZ-2022-00752
%P 1373-1382
%D 2023
%Z #LA:D120# / 2023 Apr;149(4):1373-1382
%X Perioperative systemic treatment has significantly improved the outcome in locally advanced esophagogastric cancer. However, still the majority of patients relapse and die. Data on the optimal treatment after relapse are limited, and clinical and biological prognostic factors are lacking.Patients with a relapse after neoadjuvant/perioperative treatment and surgery for esophagogastric cancer were analyzed using a prospective database. Applied treatment regimens, clinical prognostic factors and biomarkers were analyzed.Of 246 patients 119 relapsed. Among patients with a relapse event, those with an early relapse (< 6 months) had an inferior overall survival (OS 6.3 vs. 13.8 months, p < 0.001) after relapse than those with a late relapse (> 6 months). OS after relapse was longer in patients with a microsatellite-unstable (MSI) tumor. Systemic treatment was initiated in 87 patients (73
%K Esophagogastric cancer (Other)
%K MSI (Other)
%K Perioperative treatment (Other)
%K Relapse (Other)
%K Salvage treatment (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35441345
%R 10.1007/s00432-022-04016-y
%U https://inrepo02.dkfz.de/record/179574